Incyte Corporation (NASDAQ:INCY) Shares Tumble Rapidly After Melanoma Drug Experimentation Failure


Incyte Corporation (NASDAQ:INCY) shares went down rapidly after the company declared that its melanoma drug trial has failed. The company conducted the Phase 3 trial to establish the effectiveness of its drug epacadostat in combination with KEYTRUDA from Merck & Co., Inc.’s (NYSE:MRK) for treating patients suffering from metastatic or unresectable melanoma. The experiment was an effort to emphasize that epacadostat has the ability to increase the efficiency of KEYTRUDA when used together for treating newly diagnosed patients with cancer.

This failure of Incyte has affected its stocks badly. Reports say that the trial could not even meet the necessary primary endpoint that could indicate that epacadostat has the ability to lead to progression-free survival. The Merck’s shares were not as badly affected as Incyte’s which fell 21.2% to US$65.43.

After the failure in the Phase 3 trial, the two companies have declared that they will put a stop to this study. The declaration came after an external data monitoring committee found out that the trial was not successful at all in providing the new cancer patients progression-free survival. These patients were undergoing KEYTRUDA monotherapy which has been known to successfully treat and cure various forms of cancer including advanced melanoma and lung cancer.

Incyte To Continue With the Investigation

Although the two companies have halted their combined experimentation post poor performance of the Phase 3 trial, Incyte has still not lost its hope and is planning to keep on investigating the results that came out from the trial. The company is expected to present the findings of this result from the double-blind, randomized, placebo-controlled study in the upcoming scientific congress.

Around 700 patients participated in the study that focused on multiple aspects of cancers. The failure in the Phase 3 trial has brought severe disappointment to the Incyte study team. The Chief Medical Officer of the company, Steven Stein, M.D. has said that the results will surely contribute to broadening the epacadostat clinical development program.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.